How I assess comorbidities before hematopoietic cell transplantation

被引:174
作者
Sorror, Mohamed L. [1 ,2 ]
机构
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Sch Med, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Med, Div Med Oncol, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
ACUTE MYELOID-LEUKEMIA; WEIGHTED KAPPA; CO-MORBIDITY; DIFFUSING CAPACITY; CANCER-PATIENTS; HCT-CI; INDEX; DISEASE; AGREEMENT; SURVIVAL;
D O I
10.1182/blood-2012-09-455063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The hematopoietic cell transplantation-comorbidity index (HCT-CI) is a comorbidity tool suited for recipients of HCT. The index has been shown to sensitively capture the prevalence and magnitude of severity of various organ impairments before HCT and to provide valuable prognostic information after HCT. Many investigators have validated the discriminative power of the HCT-CI, but others have not. One concern is the consistency in comorbidity coding across different evaluators, particularly in view of the relatively recent addition of the HCT-CI to the transplant evaluation process. In this article, comorbidity scoring was tested across different evaluators, and only a fair interobserver agreement rate could be detected. To address these issues, a brief training program is proposed here, consisting of systematic methodology for data acquisition and consistent guidelines for comorbidity coding that were summarized in a Web-based calculator. In a validation patient cohort, this training program was shown to improve the interevaluator agreement on HCT-CI scores to an excellent rate with weighted kappa values in the range of 0.89 to 0.97. This proposed training program will facilitate reliable assessment of comorbidities in the clinic and for research studies leading to standardization of the use of comorbidities in prediction of HCT outcomes.
引用
收藏
页码:2854 / 2863
页数:10
相关论文
共 41 条
[21]   Reliability of a comorbidity measure: The index of co-existent disease (ICED) [J].
Imamura, K ;
McKinnon, M ;
Middleton, R ;
Black, N .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (09) :1011-1016
[22]   Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality [J].
Jorgensen, T. L. ;
Hallas, J. ;
Friis, S. ;
Herrstedt, J. .
BRITISH JOURNAL OF CANCER, 2012, 106 (07) :1353-1360
[23]  
Karnofsky DA, 1949, EVALUATION CHEMOTHER, P191
[24]   Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study [J].
Kataoka, K. ;
Nannya, Y. ;
Ueda, K. ;
Kumano, K. ;
Takahashi, T. ;
Kurokawa, M. .
BONE MARROW TRANSPLANTATION, 2010, 45 (03) :513-520
[25]   Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma [J].
Labonte, Laura ;
Iqbal, Tariq ;
Zaidi, Mukarram A. ;
McDiarmid, Sheyyl A. ;
Huebsch, Lothar B. ;
Tay, Jason ;
Atkins, Harold ;
Allan, David S. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (09) :1039-1044
[26]   MEASUREMENT OF OBSERVER AGREEMENT FOR CATEGORICAL DATA [J].
LANDIS, JR ;
KOCH, GG .
BIOMETRICS, 1977, 33 (01) :159-174
[27]   Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML [J].
Lim, Z. Y. ;
Ingram, W. ;
Brand, R. ;
Ho, A. ;
Kenyon, M. ;
Devereux, S. ;
Marsh, J. ;
Mufti, G. J. ;
Pagliuca, A. .
BONE MARROW TRANSPLANTATION, 2010, 45 (04) :633-639
[28]   Comorbidity measures for stroke outcome research: A preliminary study [J].
Liu, MG ;
Domen, K ;
Chino, N .
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION, 1997, 78 (02) :166-172
[29]   Reduced-intensity allogeneic transplant in patients older than 55 years: Unrelated umbilical cord blood is safe and effective for patients without a matched related donor [J].
Majhail, Navneet S. ;
Brunstein, Claudio G. ;
Tomhlyn, Marcie ;
Thomas, Avis J. ;
Miller, Jeffery S. ;
Arora, Mukta ;
Kanfinan, Dan S. ;
Burns, Linda J. ;
Slungaard, Arne ;
McGlave, Philip B. ;
Wagwer, Ohn E. ;
Weisdorf, Daniel J. .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (03) :282-289
[30]   Comparable anti leukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen [J].
Maruyama, Dai ;
Fukuda, Takahiro ;
Kato, Ruri ;
Yamasaki, Satoshi ;
Usui, Eiji ;
Morita-Hoshi, Yuriko ;
Kim, Sung-Won ;
Mori, Shin-ichiro ;
Heike, Yuji ;
Makimoto, Atsushi ;
Tajima, Kinuko ;
Tanosaki, Ryuji ;
Tobinai, Kensei ;
Takaue, Yoichi .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (08) :932-941